Myrelez (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez, is a somatostatin analog presented as a subcutaneous formulation for subcutaneous use. It treats acromegaly and gastroenteropancreatic neuroendocrine tumors in adult patients. GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Myrelez is a somatostatin analog used in endocrine‑related disorders. - Acromegaly: reduces excess growth hormone secretion and helps control disease progression. - Gastroenteropancreatic neuroendocrine tumors (GEP‑NET): inhibits hormone release and can stabilize tumor growth. - Hormone‑secreting neuroendocrine tumors: controls symptomatic hormone hypersecretion and improves clinical outcomes.

Adverse reactions may occur with lanreotide therapy. Common Side Effects: - Injection site pain or erythema - Diarrhea - Nausea or abdominal discomfort - Hyperglycemia or altered glucose tolerance - Gallbladder sludge or gallstones - Headache Serious or Rare Side Effects: - Acute pancreatitis - Severe hyperglycemia requiring medical intervention - Cardiac arrhythmias - Anaphylactic or severe allergic reactions - Injection‑site necrosis or infection - Severe hepatic dysfunction

Safety considerations are essential when using lanreotide. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus; limited data are available. - Breastfeeding: caution advised as the drug may be excreted in milk; consult a healthcare professional. - Renal impairment: monitor renal function and adjust therapy as needed. - Diabetes or impaired glucose tolerance: regularly assess blood glucose levels and manage hyperglycemia. - Gallbladder disease: monitor for signs of gallstone formation or biliary colic. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medicines. Major Interactions (Avoid): - Concomitant use of other somatostatin analogs (e.g., octreotide) may cause additive hormonal suppression. - High‑dose insulin or insulin secretagogues: risk of severe hypoglycemia when glucose control is altered. Moderate Interactions (Monitor Closely): - Oral hypoglycemic agents: may require dose adjustment due to altered glucose metabolism. - Medications affecting gastrointestinal motility (e.g., metoclopramide): potential for enhanced GI side effects. - CYP450 substrates with narrow therapeutic windows: monitor plasma levels as lanreotide can modestly affect hepatic enzyme activity.